Bionano Financial Statements From 2010 to 2024

BNGO Stock  USD 0.82  0.04  4.65%   
Bionano Genomics financial statements provide useful quarterly and yearly information to potential Bionano Genomics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bionano Genomics financial statements helps investors assess Bionano Genomics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bionano Genomics' valuation are summarized below:
Gross Profit
5.9 M
Market Capitalization
52.4 M
Enterprise Value Revenue
1.0349
Revenue
36.1 M
Earnings Share
(6.81)
We have found one hundred twenty available fundamental signals for Bionano Genomics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Bionano Genomics' prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road.

Bionano Genomics Total Revenue

37.92 Million

Check Bionano Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bionano main balance sheet or income statement drivers, such as Tax Provision of 65.1 K, Interest Income of 3.5 M or Depreciation And Amortization of 14.4 M, as well as many exotic indicators such as Price To Sales Ratio of 1.7, Dividend Yield of 0.005 or PTB Ratio of 0.64. Bionano financial statements analysis is a perfect complement when working with Bionano Genomics Valuation or Volatility modules.
  
This module can also supplement Bionano Genomics' financial leverage analysis and stock options assessment as well as various Bionano Genomics Technical models . Check out the analysis of Bionano Genomics Correlation against competitors.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.

Bionano Genomics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets142.9 M214.4 M84.7 M
Slightly volatile
Short and Long Term Debt Total92.3 M87.9 M20.1 M
Slightly volatile
Other Current Liabilities8.9 M8.1 M7.9 M
Pretty Stable
Total Current Liabilities105 M100 M25.7 M
Slightly volatile
Other Liabilities15.8 M15.1 M4.3 M
Slightly volatile
Property Plant And Equipment Net34.1 M32.5 M10.4 M
Slightly volatile
Current Deferred Revenue555.6 K783 K485.1 K
Slightly volatile
Accounts Payable5.9 M10.4 M3.6 M
Slightly volatile
Cash55.7 M53.1 M16.6 M
Slightly volatile
Non Current Assets Total48.6 M74.3 M28.4 M
Slightly volatile
Long Term Debt11.5 M18.8 M10.4 M
Slightly volatile
Cash And Short Term Investments74.8 M101.9 M43.4 M
Slightly volatile
Net Receivables5.6 M9.7 M3.8 M
Slightly volatile
Common Stock Total Equity36.2 K34.5 K10.2 K
Slightly volatile
Common Stock Shares Outstanding35.9 M34.1 M9.5 M
Slightly volatile
Long Term Debt Total11.5 M18.8 M10.4 M
Slightly volatile
Liabilities And Stockholders Equity142.9 M214.4 M84.7 M
Slightly volatile
Non Current Liabilities Total16.2 M18.2 M24.9 M
Slightly volatile
Capital Surpluse723.5 M689.1 M197.5 M
Slightly volatile
Inventory24 M22.9 M7.4 M
Slightly volatile
Other Current Assets3.2 M5.7 M2.1 M
Slightly volatile
Total Liabilities124.2 M118.2 M50.8 M
Slightly volatile
Property Plant And Equipment Gross54.1 M51.6 M12.3 M
Slightly volatile
Short and Long Term Debt84.3 M80.3 M28.3 M
Slightly volatile
Preferred Stock Total Equity37.6 M49.5 M34.9 M
Slightly volatile
Total Current Assets94.3 M140.1 M56.3 M
Slightly volatile
Non Current Liabilities Other8.4 M10.9 M5.7 M
Slightly volatile
Short Term Debt84.8 M80.8 M16.1 M
Slightly volatile
Common Stock4.8 KK6.1 K
Slightly volatile
Property Plant Equipment21.8 M20.7 M7.4 M
Slightly volatile
Deferred Long Term Liabilities137.3 K114.3 K236.4 K
Slightly volatile
Capital Stock4.8 KK6.7 K
Slightly volatile
Other Assets3.4 M3.2 M755.1 K
Slightly volatile
Intangible Assets28.4 M34 M9.8 M
Slightly volatile

Bionano Genomics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization14.4 M13.7 M2.9 M
Slightly volatile
Interest Expense5.4 M5.1 M1.5 M
Slightly volatile
Selling General Administrative98.2 M93.5 M33.9 M
Slightly volatile
Total Revenue37.9 M36.1 M13.8 M
Slightly volatile
Gross Profit4.9 M9.6 MM
Slightly volatile
Other Operating Expenses184.3 M175.5 M63.9 M
Slightly volatile
Research Development56.7 M54 M20.2 M
Slightly volatile
Cost Of Revenue27.9 M26.6 M9.5 M
Slightly volatile
Total Operating Expenses156.4 M149 M54.3 M
Slightly volatile
Reconciled Depreciation14.6 M13.9 M3.8 M
Slightly volatile

Bionano Genomics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation15.9 M15.2 M4.6 M
Slightly volatile
Begin Period Cash Flow4.8 M5.1 M9.7 M
Slightly volatile
Depreciation14.4 M13.7 M3.6 M
Slightly volatile
Other Non Cash Items84.2 M80.2 M11.4 M
Slightly volatile
Capital Expenditures1.9 M1.7 M1.6 M
Slightly volatile
Total Cash From Financing Activities89.2 M118.3 M59.4 M
Slightly volatile
End Period Cash Flow55.7 M53.1 M16.6 M
Slightly volatile
Issuance Of Capital Stock92.1 M57.7 M50 M
Slightly volatile
Dividends Paid1.6 M1.8 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.71.78719.4842
Slightly volatile
Dividend Yield0.0050.00560.0061
Slightly volatile
Days Sales Outstanding13897.6372116
Pretty Stable
Average Payables1.9 M2.5 M2.2 M
Slightly volatile
Stock Based Compensation To Revenue0.220.42030.1724
Slightly volatile
EV To Sales2.622.75299.5121
Slightly volatile
Inventory Turnover1.11.15972.2318
Pretty Stable
Days Of Inventory On Hand186315210
Slightly volatile
Payables Turnover3.272.55683.6112
Slightly volatile
Sales General And Administrative To Revenue1.671.361.5854
Slightly volatile
Average Inventory1.7 MM2.2 M
Slightly volatile
Research And Ddevelopement To Revenue1.031.49611.4319
Slightly volatile
Cash Per Share2.832.98358.7636
Slightly volatile
Capex To Operating Cash Flow0.01240.0130.0375
Slightly volatile
Days Payables Outstanding121143121
Slightly volatile
Income Quality1.050.55791.0773
Slightly volatile
Intangibles To Total Assets0.180.15840.1678
Slightly volatile
Current Ratio1.331.40082.6292
Slightly volatile
Receivables Turnover2.523.73833.318
Slightly volatile
Graham Number19.7320.7681152
Slightly volatile
Average ReceivablesM4.1 M3.3 M
Slightly volatile
Revenue Per Share1.01.057610.2904
Slightly volatile
Interest Debt Per Share2.592.725210.6522
Slightly volatile
Debt To Assets0.40.41020.3984
Slightly volatile
Operating Cycle286412323
Slightly volatile
Days Of Payables Outstanding121143121
Slightly volatile
Ebt Per Ebit0.871.6670.9934
Slightly volatile
Quick Ratio1.061.11522.1968
Slightly volatile
Net Income Per E B T1.091.00031.0026
Pretty Stable
Cash Ratio0.50.53050.9929
Pretty Stable
Cash Conversion Cycle165270202
Pretty Stable
Days Of Inventory Outstanding186315210
Slightly volatile
Days Of Sales Outstanding13897.6372116
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.0131.0453
Pretty Stable
Fixed Asset Turnover1.061.11192.1711
Very volatile
Capital Expenditure Coverage Ratio85.1976.701465.6196
Slightly volatile
Debt Ratio0.40.41020.3984
Slightly volatile
Price Sales Ratio1.71.78719.4842
Slightly volatile
Asset Turnover0.160.16840.3719
Slightly volatile
Gross Profit Margin0.340.26490.3763
Slightly volatile

Bionano Genomics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap303.4 M289 M147.4 M
Slightly volatile
Enterprise Value282.5 M269.1 M134.3 M
Slightly volatile

Bionano Fundamental Market Drivers

Cash And Short Term Investments101.9 M

Bionano Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bionano Genomics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Bionano Genomics income statement, its balance sheet, and the statement of cash flows. Bionano Genomics investors use historical funamental indicators, such as Bionano Genomics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bionano Genomics investors may use each financial statement separately, they are all related. The changes in Bionano Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bionano Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bionano Genomics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bionano Genomics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue783 K555.6 K
Total Revenue36.1 M37.9 M
Cost Of Revenue26.6 M27.9 M
Stock Based Compensation To Revenue 0.42  0.22 
Sales General And Administrative To Revenue 1.36  1.67 
Research And Ddevelopement To Revenue 1.50  1.03 
Capex To Revenue(0.05)(0.05)
Revenue Per Share 1.06  1.00 
Ebit Per Revenue(3.86)(4.05)
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bionano Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bionano Genomics' short interest history, or implied volatility extrapolated from Bionano Genomics options trading.

Pair Trading with Bionano Genomics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Bionano Stock

  0.76KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.81ME 23Andme HoldingPairCorr

Moving against Bionano Stock

  0.79YS YS Biopharma Report 22nd of April 2024 PairCorr
  0.61DOMH Dominari HoldingsPairCorr
  0.58A Agilent Technologies Financial Report 28th of May 2024 PairCorr
  0.55DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.45VCEL Vericel Corp Ord Financial Report 8th of May 2024 PairCorr
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Bionano Genomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bionano Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionano Genomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionano Genomics Stock:
Check out the analysis of Bionano Genomics Correlation against competitors.
To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.
Note that the Bionano Genomics information on this page should be used as a complementary analysis to other Bionano Genomics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Bionano Stock analysis

When running Bionano Genomics' price analysis, check to measure Bionano Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionano Genomics is operating at the current time. Most of Bionano Genomics' value examination focuses on studying past and present price action to predict the probability of Bionano Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionano Genomics' price. Additionally, you may evaluate how the addition of Bionano Genomics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Transaction History
View history of all your transactions and understand their impact on performance
Is Bionano Genomics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bionano Genomics. If investors know Bionano will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bionano Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.81)
Revenue Per Share
1.058
Quarterly Revenue Growth
0.305
Return On Assets
(0.33)
Return On Equity
(1.35)
The market value of Bionano Genomics is measured differently than its book value, which is the value of Bionano that is recorded on the company's balance sheet. Investors also form their own opinion of Bionano Genomics' value that differs from its market value or its book value, called intrinsic value, which is Bionano Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bionano Genomics' market value can be influenced by many factors that don't directly affect Bionano Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bionano Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bionano Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bionano Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.